Comparison of antigen presentation of influenza A nucleoprotein expressed in attenuated AroA- Salmonella typhimurium with that of live virus.
Rationally attenuated strains of Salmonella expressing foreign proteins represent a potentially important vaccine delivery system. The characteristics of Ag presentation of influenza nucleoprotein expressed in an AroA- strain of Salmonella typhimurium (SL3262-pNP-2) have therefore been compared with those of soluble purified nucleoprotein (NP) and infectious influenza virus. This represents three distinct modes of internalization of the same protein into APC. Human monocytes and the monocytic leukemia cell line THP-1 infected with SL3261-pNP-2 were found to present several different epitopes from NP to human CD4+ class II-restricted T lymphocytes. Ag presentation to these T cell clones was enhanced by pretreatment of THP-1 cells with IFN-gamma but not TNF-alpha. Bacterial phagocytosis and Ag presentation of NP were increased after opsonization of Salmonella with immune serum. Macrophages infected with SL3261-pNP-2 were unable to present NP to class I-restricted T cells. In contrast, cells infected with live influenza virus, although recognized by NP-specific class I-restricted CTL, were inefficiently recognized by NP-specific class II-restricted T cells. Ag presentation to CD4+ T cell clones by monocytes of SL3261-pNP-2, purified recombinant NP, and live influenza virus, but not the synthetic peptide 206-229, was inhibited by chloroquine and the protease inhibitors pepstatin A and leupeptin, suggesting that the major route of processing in each case was via the exogenous pathway. T cell recognition of NP via all of these Ag delivery systems was also abrogated by cycloheximide and brefeldin A treatment, indicating a requirement for recently synthesized MHC class II molecules in presentation of whole NP after processing but not for the corresponding synthetic peptide.
Brett
S J
SJ
Department of Cell Biology, Wellcome Research Laboratories, Beckenham, Kent, UK.
Rhodes
J
J
Liew
F Y
FY
Tite
J P
JP
D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase; D019883:Alkyl and Aryl Transferases; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology*; D020126:Brefeldin A; D003513:Cycloheximide / Q000494:pharmacology; D003517:Cyclopentanes / Q000494:pharmacology; D000939:Epitopes / Q000276:immunology; D005260:Female; D005822:Genetic Vectors; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D009980:Influenza A virus / Q000276:immunology* / Q000472:pathogenicity; D007700:Kinetics; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009000:Monocytes / Q000276:immunology / Q000382:microbiology; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins / Q000276:immunology*; D010587:Phagocytosis; D011480:Protease Inhibitors / Q000494:pharmacology; D016601:RNA-Binding Proteins; D012486:Salmonella typhimurium / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D014407:Tumor Cells, Cultured; D014758:Viral Core Proteins / Q000276:immunology*; D014774:Virulence
D000945:Antigens, Differentiation, T-Lymphocyte; D001426:Bacterial Proteins; D003517:Cyclopentanes; D000939:Epitopes; D015395:Histocompatibility Antigens Class I; C048842:NP protein, Influenza A virus; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D011480:Protease Inhibitors; D016601:RNA-Binding Proteins; D014758:Viral Core Proteins; D020126:Brefeldin A; D003513:Cycloheximide; D019883:Alkyl and Aryl Transferases; D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase